Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.
(1)
Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia.
The new collaboration further expands Boehringer Ingelheim s circuitry-based approach to precision psychiatry and solidifies the company s commitment to provide better treatments for patients living with serious mental health conditions.
Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia. Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim s deep experience in central n